VSTM News

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Verastem Oncology to Present at Jefferies Healthcare Conference

Form 8-K

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Form 8-K

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026